Enterprise Value
7.532M
Cash
48.48M
Avg Qtr Burn
-7.272M
Short % of Float
3.39%
Insider Ownership
5.43%
Institutional Own.
40.27%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EYSUVIS™ (loteprednol etabonate ophthalmic suspension) Details Dry Eye Disease | Approved Quarterly sales | |
INVELTYS™ (loteprednol etabonate ophthalmic suspension) Details Post-operative ocular inflammation and pain | Approved Quarterly sales | |
KPI-012 Details Persistent Corneal Epithelial Defect | Phase 2b Data readout |